RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
RY_SW01 Cell Injection's preclinical research results have shown that the injection
significantly improved urine biochemical indicators and tissue damage in two lupus nephritis
animal models after MSC administration, with no occurrence of rejection and excellent safety.
The mechanism of action of RY_SW01 Cell Injection is relatively clear, demonstrating
favorable therapeutic effects in preclinical animal models. Compared to existing conventional
therapies, it has the advantages of "convenient treatment and sustained efficacy." It may
help reduce the variety and quantity of drugs administered to patients and the various side
effects associated with drug treatment. In some cases, it may even lead to the
discontinuation of immunosuppressive drugs, reducing mortality and disability rates while
improving the quality of life for patients. Its unique advantages have the potential to
fundamentally change the current clinical treatment landscape and offer promising prospects
for clinical application.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu Renocell Biotech Company
Collaborator:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School